Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GDTCNASDAQ:SAVANASDAQ:SGMTNASDAQ:TVRD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGDTCCytoMed Therapeutics$2.33+1.0%$2.34$1.20▼$4.05$25.53M-0.3177,973 shs17,114 shsSAVACassava Sciences$2.04-2.9%$1.66$1.15▼$42.20$98.55M-2.313.00 million shs984,159 shsSGMTSagimet Biosciences$3.50+2.9%$3.00$1.73▼$7.38$107.36M2.32852,185 shs948,484 shsTVRDCara Therapeutics$29.86-3.2%$0.00$8.13▼$34.31$93.01M0.2120,937 shs53,935 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGDTCCytoMed Therapeutics-2.52%+10.71%-3.53%-15.45%+13.41%SAVACassava Sciences-1.41%+2.44%+32.08%-19.23%-90.31%SGMTSagimet Biosciences+1.19%+5.59%+2.72%-5.82%-34.24%TVRDCara Therapeutics-7.58%+3,085,999,900.00%+3,085,999,900.00%+3,085,999,900.00%+3,085,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGDTCCytoMed Therapeutics1.9635 of 5 stars3.53.00.00.03.30.00.0SAVACassava Sciences3.7837 of 5 stars3.31.00.04.73.30.01.3SGMTSagimet Biosciences2.6613 of 5 stars3.43.00.00.02.32.50.6TVRDCara TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGDTCCytoMed Therapeutics 3.00Buy$5.00114.22% UpsideSAVACassava Sciences 2.50Moderate Buy$54.502,571.57% UpsideSGMTSagimet Biosciences 2.80Moderate Buy$22.40540.00% UpsideTVRDCara Therapeutics 3.00Buy$65.00117.68% UpsideCurrent Analyst Ratings BreakdownLatest GDTC, TVRD, SGMT, and SAVA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2025TVRDCara TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$65.003/25/2025SAVACassava SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$2.00 ➝ $2.003/11/2025SGMTSagimet BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.003/4/2025SAVACassava SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGDTCCytoMed Therapeutics$69.50K367.39N/AN/A$0.78 per share2.99SAVACassava SciencesN/AN/AN/AN/A$3.26 per shareN/ASGMTSagimet Biosciences$2M53.68N/AN/A$3.98 per share0.88TVRDCara TherapeuticsN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGDTCCytoMed Therapeutics-$3.13MN/A0.00∞N/AN/AN/AN/AN/ASAVACassava Sciences-$97.22M-$1.50N/AN/AN/AN/A-88.05%-64.98%8/14/2025 (Estimated)SGMTSagimet Biosciences-$27.88M-$1.76N/AN/AN/AN/A-23.63%-22.91%8/13/2025 (Estimated)TVRDCara TherapeuticsN/AN/A0.00∞N/AN/AN/AN/AN/ALatest GDTC, TVRD, SGMT, and SAVA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025SAVACassava SciencesN/A-$0.48N/A-$0.48N/AN/A5/8/2025Q1 2025SGMTSagimet Biosciences-$0.79-$0.56+$0.23-$0.56N/AN/A3/12/2025Q4 2024SGMTSagimet Biosciences-$0.65-$0.50+$0.15-$0.50N/AN/A3/3/2025Q4 2024SAVACassava Sciences-$0.68-$0.57+$0.11-$0.57N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGDTCCytoMed TherapeuticsN/AN/AN/AN/AN/ASAVACassava SciencesN/AN/AN/AN/AN/ASGMTSagimet BiosciencesN/AN/AN/AN/AN/ATVRDCara TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGDTCCytoMed Therapeutics0.0421.54N/ASAVACassava SciencesN/A3.553.55SGMTSagimet BiosciencesN/A38.4138.41TVRDCara TherapeuticsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGDTCCytoMed Therapeutics0.04%SAVACassava Sciences38.05%SGMTSagimet Biosciences87.86%TVRDCara Therapeutics44.66%Insider OwnershipCompanyInsider OwnershipGDTCCytoMed TherapeuticsN/ASAVACassava Sciences2.40%SGMTSagimet Biosciences14.70%TVRDCara Therapeutics3.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGDTCCytoMed TherapeuticsN/A10.94 millionN/ANot OptionableSAVACassava Sciences3048.31 million43.78 millionOptionableSGMTSagimet Biosciences830.68 million25.28 millionOptionableTVRDCara Therapeutics803.12 millionN/AN/AGDTC, TVRD, SGMT, and SAVA HeadlinesRecent News About These CompaniesTvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary FibrosisMay 27 at 8:00 AM | businesswire.comCara Therapeutics (NASDAQ:TVRD) Upgraded at Wall Street ZenMay 27 at 1:15 AM | americanbankingnews.comCara Therapeutics (NASDAQ:TVRD) Earns Outperform Rating from Analysts at OppenheimerMay 26 at 6:10 AM | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGDTC, TVRD, SGMT, and SAVA Company DescriptionsCytoMed Therapeutics NASDAQ:GDTC$2.33 +0.02 (+1.04%) Closing price 03:57 PM EasternExtended Trading$2.27 -0.06 (-2.70%) As of 04:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company was incorporated in 2018 and is headquartered in Singapore.Cassava Sciences NASDAQ:SAVA$2.04 -0.06 (-2.86%) Closing price 04:00 PM EasternExtended Trading$2.06 +0.02 (+0.98%) As of 04:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.Sagimet Biosciences NASDAQ:SGMT$3.50 +0.10 (+2.94%) Closing price 04:00 PM EasternExtended Trading$3.50 0.00 (0.00%) As of 04:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.Cara Therapeutics NASDAQ:TVRD$29.86 -1.00 (-3.24%) As of 04:00 PM EasternCara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hormel Stock Near Lows, But Tariff Relief Could Boost Outlook Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Intel's Loss Is Broadcom's Gain as AVGO Dominates Networking Target's Big Bet: Is It a Cheap Stock or a Value Trap? Dividend Investors Looking for an Edge? 3 Stocks Insiders Bought Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
